Alzamend Neuro Inc (ALZN)vsJohnson & Johnson (JNJ)
ALZN
Alzamend Neuro Inc
$1.21
-0.82%
HEALTHCARE · Cap: $6.27M
JNJ
Johnson & Johnson
$273.25
-0.73%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
ALZN
Avoid28
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALZN.
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$273.25
$129.13 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALZN
The strongest argument for ALZN centers on Price/Book.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : ALZN
The primary concerns for ALZN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ALZN profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
ALZN carries more volatility with a beta of 0.27 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 28/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alzamend Neuro Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alzamend Neuro Inc. is an innovative biotechnology company poised to revolutionize the treatment landscape for neurodegenerative diseases, especially Alzheimer's disease. Utilizing a proprietary drug development platform and a robust intellectual property portfolio, the company is strategically positioned to meet significant unmet medical needs in the pharmaceutical market. With a commitment to advancing its therapeutic candidates through rigorous clinical trials and fostering strategic partnerships, Alzamend Neuro aims to enhance patient quality of life and make substantial contributions to the neurotherapeutics sector. Its focused approach on critical neurological health challenges presents a compelling investment opportunity within the biotech industry.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?